Shionogi & Co., Ltd. (SGIOF) Stock Price, News & Analysis

Company Overview

Shionogi & Co., Ltd., established in 1878 and headquartered in Osaka, Japan, is a research-driven pharmaceutical company known for its focus on infectious diseases, pain management, cardiovascular-metabolic conditions, and central nervous system disorders. Over its more than a century-long history, Shionogi has built a diverse portfolio through both in-house development and strategic collaborations, bringing a range of innovative therapies to market, particularly in the field of anti-infectives and antiviral treatments.

In the anti-infectives segment, Shionogi is widely recognized for its efforts to combat antimicrobial resistance, with key products such as the carbapenem antibiotic doripenem. The company has also advanced antiviral agents for influenza and other viral infections, often in partnership with global industry leaders to support broader public health initiatives. Beyond infectious diseases, Shionogi’s R&D pipeline includes novel analgesics for acute and chronic pain and investigational programs addressing metabolic disorders and neurological conditions.

Shionogi extends its operations across Japan, North America, Europe and the Asia-Pacific region through subsidiaries, licensing agreements and co-development partnerships. This international footprint is reinforced by alliances with leading pharmaceutical firms, enabling the company to accelerate development timelines and expand global distribution networks. Guided by a commitment to scientific excellence and patient-centric innovation, Shionogi continues to invest heavily in research, seeking to address unmet medical needs and improve health outcomes worldwide.

Key Stats

• Today's Range: $15.75 to $16.50
• 50-Day Range: $15.20 to $18.05
• 52-Week Range: $12.21 to $18.05
• Volume: 300 shs
• Average Volume: 1,188 shs
• Market Capitalization: N/A
• P/E Ratio: 0.17
• Dividend Yield: 121.26%
• Price Target: N/A
• Consensus Rating: N/A

Shionogi & Co., Ltd. Stock Analysis - MarketRank™

Shionogi & Co., Ltd. scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Shionogi & Co., Ltd..

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Shionogi & Co., Ltd. is 0.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.49.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shionogi & Co., Ltd. is 0.17, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.01.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Shionogi & Co., Ltd. has a short interest ratio ("days to cover") of 9399, which indicates bearish sentiment.

Change versus previous month

Short interest in Shionogi & Co., Ltd. has recently decreased by 2.09%, indicating that investor sentiment is improving.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Shionogi & Co., Ltd. pays a meaningful dividend of 1.14%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Shionogi & Co., Ltd. does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Shionogi & Co., Ltd. is 21.00%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Shionogi & Co., Ltd. has a short interest ratio ("days to cover") of 9399, which indicates bearish sentiment.

Change versus previous month

Short interest in Shionogi & Co., Ltd. has recently decreased by 2.09%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

Shionogi & Co., Ltd. has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Shionogi & Co., Ltd. this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shionogi & Co., Ltd. insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 22.59% of the stock of Shionogi & Co., Ltd. is held by institutions.

SGIOF Stock Analysis - Frequently Asked Questions

How have SGIOF shares performed this year?

Shionogi & Co., Ltd.'s stock was trading at $12.21 at the beginning of the year. Since then, SGIOF shares have increased by 29.0% and is now trading at $15.75.

How do I buy shares of Shionogi & Co., Ltd.?

Shares of SGIOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/19/2025
• Next Earnings (Estimated): 7/28/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:SGIOF
• CIK: 1281721
• Web: www.shionogi.co.jp
• Phone: (166) 202-2161
• Fax: N/A
• Employees: 5,690
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.17
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A